mirdametinib (PD-0325901)

News alerts, weekly reports and conference planners

Company:

SpringWorks Therap

Drug class:

MEK inhibitor

Related drugs:

NF1 deletion	Glioblastoma	NF1 deletion	Glioblastoma	PD-0325901 Sensitive: C4 – Case Studies PD-0325901 Sensitive : C4	PD-0325901 Sensitive: C4 – Case Studies PD-0325901 Sensitive : C4
KRAS mutation	Solid Tumor	KRAS mutation	Solid Tumor	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D
PTEN deletion	Ovarian Cancer	PTEN deletion	Ovarian Cancer	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D
KRAS G12D	Ovarian Cancer	KRAS G12D	Ovarian Cancer	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D	PD-0325901 + PF-04691502 Sensitive: D – Preclinical PD-0325901 + PF-04691502 Sensitive : D
KRAS mutation	Colon Cancer	KRAS mutation	Colon Cancer	PF-05212384 + PD-0325901 Sensitive: D – Preclinical PF-05212384 + PD-0325901 Sensitive : D	PF-05212384 + PD-0325901 Sensitive: D – Preclinical PF-05212384 + PD-0325901 Sensitive : D
PIK3CA mutation	Colon Cancer	PIK3CA mutation	Colon Cancer	PF-05212384 + PD-0325901 Sensitive: D – Preclinical PF-05212384 + PD-0325901 Sensitive : D	PF-05212384 + PD-0325901 Sensitive: D – Preclinical PF-05212384 + PD-0325901 Sensitive : D
NF1 deletion	Acute Myelogenous Leukemia	NF1 deletion	Acute Myelogenous Leukemia	PD-0325901 Resistant: D – Preclinical PD-0325901 Resistant : D	PD-0325901 Resistant: D – Preclinical PD-0325901 Resistant : D
RASGRP1 overexpression	Acute Myelogenous Leukemia	RASGRP1 overexpression	Acute Myelogenous Leukemia	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
NRAS mutation	Endometrial Cancer	NRAS mutation	Endometrial Cancer	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
HRAS mutation	Endometrial Cancer	HRAS mutation	Endometrial Cancer	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
miR-135-b expression	Pancreatic Cancer	miR-135-b expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
miR-200-b expression	Pancreatic Cancer	miR-200-b expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
miR-139-5p expression	Pancreatic Cancer	miR-139-5p expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
miR-200-a expression	Pancreatic Cancer	miR-200-a expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	PD-0325901 Resistant: D – Preclinical PD-0325901 Resistant : D	PD-0325901 Resistant: D – Preclinical PD-0325901 Resistant : D
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
miR-200-c expression	Pancreatic Cancer	miR-200-c expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
miR-141 expression	Pancreatic Cancer	miR-141 expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
miR-429 expression	Pancreatic Cancer	miR-429 expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
miR-155 expression	Pancreatic Cancer	miR-155 expression	Pancreatic Cancer	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D	erlotinib + PD-0325901 Sensitive: D – Preclinical erlotinib + PD-0325901 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D
NF1 mutation	Melanoma	NF1 mutation	Melanoma	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	PD-0325901 + BGB-3245 Sensitive: D – Preclinical PD-0325901 + BGB-3245 Sensitive : D	PD-0325901 + BGB-3245 Sensitive: D – Preclinical PD-0325901 + BGB-3245 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D
BRAF V595E	Prostate Cancer	BRAF V595E	Prostate Cancer	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
BCR-ABL1 T315I	Leukemia	BCR-ABL1 T315I	Leukemia	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D

mirdametinib (PD-0325901)

Associations
(30)

Associations
(30)

mirdametinib (PD-0325901)

Associations(30)

Associations(30)

Associations
(30)

Associations
(30)